Insider Buying: CorMedix (NASDAQ:CRMD) Director Purchases 25,000 Shares of Company Stock

CorMedix Inc (NASDAQ:CRMD – Get Free Report) Director Myron Kaplan acquired 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were purchased at an average price of $4.88 per share, with a total value of $122,000.00. Following the completion of the acquisition, the director owned 256,487 shares of the company’s stock, valued at $1,251,656.56. This represents a 10.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CorMedix Stock Down 3.6%

Shares of CRMD stock traded down $0.17 during trading on Wednesday, reaching $4.50. The company’s stock had a trading volume of 1,600,703 shares, compared to its average volume of 1,632,172. CorMedix Inc has a one year low of $4.49 and a one year high of $13.02. The business has a fifty day moving average price of $7.04 and a 200-day moving average price of $7.54. The company has a market cap of $357.93 million, a price-to-earnings ratio of 6.52, a price-to-earnings-growth ratio of 1.11 and a beta of 1.48. The company has a quick ratio of 2.36, a current ratio of 2.43 and a debt-to-equity ratio of 0.31.

CorMedix (NASDAQ:CRMD – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million during the quarter, compared to analyst estimates of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. Analysts anticipate that CorMedix Inc will post 0.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRMD has been the subject of a number of recent analyst reports. Needham & Company LLC increased their price target on shares of CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Wall Street Zen lowered shares of CorMedix from a “hold” rating to a “sell” rating in a research note on Saturday. Royal Bank Of Canada upped their target price on shares of CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, November 10th. Weiss Ratings downgraded shares of CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, November 10th. Finally, UBS Group set a $19.00 price target on CorMedix in a report on Tuesday, November 10th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, CorMedix currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.22.

View Our Latest Stock Analysis on CorMedix

Institutional Investors Weigh In On CorMedix

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in CorMedix in the second quarter valued at about $49,644,000. Goldman Sachs Group Inc. boosted its position in shares of CorMedix by 167.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company’s stock worth $9,620,000 after acquiring an additional 782,989 shares in the last quarter. Marshall Wace LLP increased its stake in CorMedix by 53.4% in the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock valued at $9,205,000 after acquiring an additional 415,887 shares during the last quarter. Pacer Advisors Inc. raised its position in CorMedix by 128.7% during the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock valued at $3,942,000 after purchasing an additional 326,724 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of CorMedix by 150.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock valued at $3,443,000 after purchasing an additional 263,618 shares during the last quarter. Institutional investors own 34.18% of the company’s stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Recommended Stories

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.